Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Non-Current Deffered Revenue (2018 - 2026)

Profound Medical has reported Non-Current Deffered Revenue over the past 8 years, most recently at $388000.0 for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue rose 691.84% year-over-year to $388000.0; the TTM value through Dec 2025 reached $388000.0, up 691.84%, while the annual FY2025 figure was $388000.0, 691.84% up from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $388000.0 at Profound Medical, up from $148000.0 in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $875000.0 in Q4 2021 and troughed at $49000.0 in Q4 2024.
  • A 5-year average of $388875.0 and a median of $268000.0 in 2025 define the central range for Non-Current Deffered Revenue.
  • Biggest five-year swings in Non-Current Deffered Revenue: plummeted 93.27% in 2024 and later skyrocketed 691.84% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $875000.0 in 2021, then decreased by 12.69% to $764000.0 in 2022, then dropped by 4.71% to $728000.0 in 2023, then plummeted by 93.27% to $49000.0 in 2024, then skyrocketed by 691.84% to $388000.0 in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for PROF at $388000.0 in Q4 2025, $148000.0 in Q3 2025, and $74000.0 in Q2 2025.